ArticleCancer chemotherapy and pharmacology2019

A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).

Jeffrey Melson Clarke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.